Investors

Stock price graph
     

BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3® Test, is focused on the development and delivery of diagnostic solutions to aid in the clinical management of heart failure and related disorders.

View all »   RSSRecent Releases

Feb 2, 2015
BG Medicine Announces Receipt of Favorable NASDAQ Listing Determination

Nov 20, 2014
BG Medicine, Inc. Welcomes Presentation of Clinical Data on Galectin-3 Testing at the American Heart Association 2014 Scientific Sessions Conference